Skip to main content

CORRECTION article

Front. Pharmacol., 12 August 2022
Sec. Pharmacology of Anti-Cancer Drugs

Corrigendum: TEOA inhibits proliferation and induces DNA damage of diffuse large B-cell lymphoma cells through activation of the ROS-dependent p38 MAPK signaling pathway

Xingxing Yu,&#x;Xingxing Yu1,2Xin Wang&#x;Xin Wang1Xu Wang,&#x;Xu Wang3,4Yi Zhou,Yi Zhou1,5Yanchun LiYanchun Li6Aiwei WangAiwei Wang7Tongtong WangTongtong Wang5Yihan AnYihan An1Weidong SunWeidong Sun1Jing Du
Jing Du4*Xiangmin Tong,,,
Xiangmin Tong1,3,6,8*Ying Wang
Ying Wang8*
  • 1Clinical Research Institute, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China
  • 2Department of Hematology, Fuyang Hospital of Anhui Medical University, Fuyang, China
  • 3School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China
  • 4Department of Laboratory Medicine, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China
  • 5Wangjiangshan Institute, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China
  • 6The Second Clinical Medical School of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
  • 7Department of Hematology, The First People’s Hospital of Fuyang, Hangzhou, China
  • 8Phase I Clinical Research Center, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

A Corrigendum on
TEOA inhibits proliferation and induces DNA damage of diffuse large B-cell lymphoma cells through activation of the ROS-dependent p38 MAPK signaling pathway

by Yu, X, Wang, X, Wang, X, Zhou, Y, Li, Y, Wang, A, Wang, T, An, Y, Sun, W, Du, J, Tong, X and Wang, Y (2020). Front. Pharmacol. 11:554736. doi: 10.3389/fphar.2020.554736

In the published article, there was an error in Figures 3E, 4E as published. The images of Vehicle in Figure 3E and TEOA + GSH in Figure 4E were incorrect. The corrected Figures 3E, 4E and its caption appear below.

FIGURE 3
www.frontiersin.org

FIGURE 3. TEOA affected the expression of apoptosis-related protein in OCI-LY10 cells. (A) Diffuse large B-cell lymphoma (DLBCL) cells were exposed to various concentrations of TEOA for 12 h. The expression of the following apoptosis-related proteins was determined by western blot: cleaved PARP, caspase-3, and Bcl-2 family members Bcl-2, Bad, and Bax; β-actin was used as a loading control. (B) The quantitation of cleaved PARP, caspase-3, Bcl-2, Bad, and Bax were shown. ∗p < 0.05; ∗∗p < 0.01. (C) OCI-LY10 cells were treated with different doses of TEOA for 12 h. The expression of P53, P21, P27, and g-H2AX protein was determined by western blot; β-actin was used as a loading control. (D) The quantitation of P53, P21, P27, and γ-H2AX. Data were presented as mean ± SD. ∗p < 0.05; ∗∗p < 0.01. (E) OCI-LY10 cells were treated with 25 μM TEOA for 12 h and stained with γ-H2AX (1:200) antibody. DAPI was used for nucleus staining. Images were acquired with the confocal laser scanning microscopy.

FIGURE 4
www.frontiersin.org

FIGURE 4. | TEOA increased the production of cellular ROS and promoted apoptosis. (A) OCI-LY10 cells were exposed to different concentrations of TEOA for 12 h, then treated cells were stained with DCF-DA for 30 min, cellular ROS levels were determined by flow cytometry. (B) Quantitative analysis of the cellular ROS, ∗p < 0.05. OCI-LY10 and OCI-LY3 cells were treated with TEOA for 12 h in the presence or absence of NAC and GSH, cell death was determined by CCK8 assay (C,D) and PI staining (E). (F) Flow cytometry was used to detect apoptosis in DLBCL cells exposed to TEOA with or without NAC treatment. (G) The proportion of apoptotic cells was shown on the right, ∗p < 0.01.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: TEOA, diffuse large B-cell lymphoma, DNA damage, reactive oxygen species, p38 MAPK

Citation: Yu X, Wang X, Wang X, Zhou Y, Li Y, Wang A, Wang T, An Y, Sun W, Du J, Tong X and Wang Y (2022) Corrigendum: TEOA inhibits proliferation and induces DNA damage of diffuse large B-cell lymphoma cells through activation of the ROS-dependent p38 MAPK signaling pathway. Front. Pharmacol. 13:973989. doi: 10.3389/fphar.2022.973989

Received: 20 June 2022; Accepted: 01 July 2022;
Published: 12 August 2022.

Edited and reviewed by:

Xu Zhang, Jiangsu University, China

Copyright © 2022 Yu, Wang, Wang, Zhou, Li, Wang, Wang, An, Sun, Du, Tong and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ying Wang, nancywangying@163.com; Jing Du, dujing1@hmc.edu.cn; Xiangmin Tong, tongxiangmin@163.com

These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.